Index of Articles From AIDS Treatment News

1998
-
Issue #309, December 18, 1998
-
Complementary Treatments: Dr. Kaiser's New Book
-
AIDS Treatment News January Publication Schedule
-
Buyers' Club List, December 1998
-
AIDS Treatment News Index, 1998
Advertisement
-
Issue #308, December 4, 1998
-
Major Vaccine Project: Largest AIDS Research Grants Ever to Two "Most Promising" Approaches
-
Disability and Returning to Work: Proposed Change to Let Disabled Keep Benefits
-
Low-Dose Cyclosporin: Government Trial Recruiting, CD4 Count Over 500
-
IDSA Conference: Abstracts on the Web
-
4th International Congress on Drug Therapy in HIV Infection: Summaries on Web
-
New Drug Pricing: Progress on World AIDS Day?
-
Issue #307, November 20, 1998
-
GATT and the Gap: How to Save Lives
-
Testosterone Cream and Gel Available; Prices Vary Greatly
-
Urgent: Medicaid Rule Changes, Comments Due November 30
-
Health Insurance: New NAPWA Guide
-
Flu Season Protection: Information on Web
-
Retroviruses Conference: Press Must Register by December 31 or Earlier
-
Medical Marijuana Wins 7 of 7 U.S. Elections
-
Northern California: HIV Advocacy Conference, December 12-13
-
Free Newsletter Subscriptions Through Medical Practices, Clinics
-
Issue #306, November 6, 1998
-
T-20 Results Published
-
U.S. Testosterone Shortage: Call for Information
-
Abacavir (ZiagenTM) Approval Recommended
-
Induction/Maintenance Strategy Failed in U.S., French Trials
-
Efavirenz (SustivaTM) Available through Patient Assistance Program
-
Amprenavir (AgeneraseTM) Submitted for Approval
-
National AIDS Treatment Advocates Forum, December 5-8, Philadelphia
-
Glasgow Conference Reports on Web
-
Lipodystrophy, Anemia, Resistance, Other Articles at www.healthcg.org/hiv
-
New TB Guidelines for Persons with HIV
-
Alitretinoin Gel (Panretin®) FDA Hearing November 16
-
Record AIDS Funding from Outgoing Congress
-
Help Wanted, AIDS Treatment Writer, New York
-
California: Medicaid Expansion Needs Quick Attention after the Election
-
Youth Consent, Confidentiality for Counselors, San Francisco December 1
-
California ADAP Update
-
Issue #305, October 16, 1998
-
Retroviruses Conference Scholarship Deadline Nov. 3
-
AmFAR RFPs: Immune Reconstitution, HIV Vaccines; Grants $75,000 to $150,000, Letter Due November 4
-
Oakland, California: October 22 Panel on Alternative Treatments
-
Help Wanted, AIDS Treatment Writer, New York
-
Nelfinavir (Viracept®) Price Increase 4.6%
-
11th National HIV/AIDS Update Conference; Abstract Deadline November 1
-
Association of Nurses in AIDS Care, November 15-18, San Antonio
-
San Francisco: Hepatitis C Community Forum, October 20
-
Cannabis and Cannabidiol: Interview with Robert Gorter, M.D.
-
California ADAP Alert
-
Issue #304, October 2, 1998
-
Efavirenz (SUSTIVATM) Approved
-
Crixivan® (Indinavir): Three Doses Daily, Not Two, in Most Regimens
-
Amprenavir (AgeneraseTM) Now Available in Expanded Access
-
Successful Standard Treatment for Lipid Abnormalities: Experience with 44 Patients
-
San Francisco: Body Shape Changes and Lipodystrophy -- Community Forum October 19
-
ICAAC Conference: Daily Summaries Available
-
Abacavir (ZiagenTM) Advisory Committee Meeting, November 2
-
Prison Treatment Programs: Glaxo-Wellcome Awards 19 Grants
-
Iscador Update: Interview with Robert Gorter, M.D.
-
United States Conference on AIDS, Dallas, Oct. 29 - Nov. 1
-
San Francisco: POZ Life Expo, October 16-17
-
Issue #303, September 18, 1998
-
Lipodystrophy Research Coordination Needed
-
ICAAC Report, September 27, by Telephone Conference
-
PMPA Trials Recruiting
-
Improved Viral Load Test: Open Letter on FDA Approval
-
Acupuncture Research Symposium, Sept. 26-27 at Stanford University
-
Indigenous Nations AIDS Conference, Prior Lake, Minnesota, September 27-30
-
Titillationism -- Or, Register Now to Vote!
-
Issue #302, September 4, 1998
-
Post-Exposure Prevention (PEP); What to Do If the Condom Breaks?
-
New Drug Pricing Consensus Letter, Sign-Ons Requested
-
Hepatitis C: New Treatment Overview
-
HIV and Hepatitis Physician Education, San Francisco Sept. 12
-
IHV 1998 Annual Meeting ("Gallo Lab Meeting"); Program, Many Talks on Web
-
Fomivirsen Approved for CMV Retinitis: First Antisense Drug
-
Prison Issues: National Conference, Web Sites
-
Help Wanted: Executive Director, Project Inform
-
Issue #301, August 21, 1998
-
The CHORUS Database on Patient Clinical Care -- and Interview with Stephen Becker, M.D.
-
Retroviruses Conference, Jan. 31 - Feb. 4, 1999, Chicago: Abstract Deadline October 1
-
International Healthcare Resource Allocation Conference, November 15-18, Cancun, Mexico
-
Herbal Medicine Safety Workshop, National Institutes of Health, Research Triangle Park, September 23 and 24
-
Medical Marijuana: Strong Support in Oakland
-
San Francisco: Forum on Body Composition Changes, September 1
-
San Francisco: Intensive Seminar on Benefits, September 10-11
-
Help Wanted: Assistant Director, Forum for Collaborative HIV Research
-
Major Email Security Flaws Discovered: How to Protect Your Data
-
Issue #300, August 7, 1998
-
T-20: New Trial Enrolling, 9 U.S. Cities
-
New Vaccine+HAART Treatment Trial Enrolling at NIH
-
Ritonavir Capsule Manufacturing Problems Will Require Switch to Liquid Formulation
-
Geneva Medical Report Now on Web
-
Viral Load: Roche Applies for Marketing Approval for UltraSensitive Test
-
IHV 1998 Annual Meeting (Gallo Lab Meeting) August 23-29 in Baltimore
-
Geneva Update Town Hall Meeting, August 17, Redwood City, California
-
San Francisco: Employment-Issues Training for Service Providers, August 19
-
AIDS Meals and Nutrition Conference, September 10-13, San Francisco
-
Rural AIDS Conference, Sept. 10-12, Albuquerque
-
Hepatitis C Conference, August 23-25 in Oakland
-
Medical Marijuana: Healing Alternatives Begins Distribution
-
Nutritional Supplements: Call for Information
-
Issue #299, July 17, 1998
-
Efavirenz (Sustiva) May Equal or Exceed Protease Inhibitor in Initial Antiretroviral Combination
-
Viral Resistance Overview
-
Fusion inhibitors, T-20; Chemokine Variants; Tat and Interferon Antibodies: Gallo Describes Three New Treatment Approaches
-
Geneva Conference: Finding Information on the Web and Elsewhere
-
AIDS Diarrhea: Phase III Trial Recruiting in Over 30 U.S. Sites
-
San Francisco: Geneva Conference Review, July 22
-
Issue #298, July 10, 1998
-
HIV-Specific Immune Responses Restored by HIV Immunogen Plus Antiretroviral Suppression
-
Successful Treatment of "Buffalo Hump" with Growth
Hormone
-
Geneva Conference Treatment Highlights
-
AIDS Treatment News Internet Directory
-
Women's Treatment Information and Advocacy: Position at Project Inform
-
San Francisco, Oakland: Treatment Access and Information Workshop, July 24, July 31, or August 14
-
Scientific American July Special Report on AIDS
-
Issue #297, June 22, 1998
-
Agouron and Immune Response to Commercialize Remune Immune-Based Treatment
-
12th World AIDS Conference, Geneva, June 28 - July 3: How to Participate from Home
-
Geneva Arrangements (If You Are Going)
-
Metabolic Complications, Growth Hormone Treatment: New Studies Planned
-
Ribavirin Approved for Hepatitis C Combination Treatment
-
Pediatric HIV Treatment: Federal Guidelines Discussed July 22
-
Congress: How You Can Help
-
San Francisco: Six-Week Workshop on Returning to Work
-
Issue #296, June 5, 1998
-
New Guide to Living with HIV Infection
-
Medical Marijuana: Largest Provider Closed, Some Alternatives Available
-
Medical Marijuana Distribution Summit, Sacramento: Video Available
-
Efavirenz (Sustiva, DMP 266) and Saquinavir (Fortovase®) Combination: Pharmacologic Interaction
-
If You Are Exposed to HIV: Guidelines Published for Postexposure Prevention
-
Medical Marijuana Study in San Francisco: Pays $1000, 25 Days in Hospital
-
Acetylcarnitine and Neuropathy: Call for Information
-
Prison or Discharge Treatment Programs: Funding Available, Proposals Due June 29
-
Correction: Hepatitis C Trial
-
Email Experts; Librarians: AIDS Treatment News Seeks Expert Advice
-
Prospective Case Series in Clinical Trial Design -- Proposal, and NTZ Example
-
Issue #295, May 15, 1998
-
Hepatitis C Important Treatment Advance: Interview with Douglas Dieterich, M.D.
-
Hepatitis C and HIV: Ribavirin Plus Interferon Study Recruiting
-
Metabolic Changes: Concerns About Heart, Circulatory Risks
-
NTZ: Advisory Committee Votes Against Approval
-
Update on AIDS Wasting and Lipodystrophy: One-Day Seminar in Geneva, June 28
-
Geneva Conference: Call for Alternative and Traditional Healing Practices Material
-
AIDS Vaccine: Major Report Available
-
Issue #294, May 1, 1998
-
VIAGRA Warning re "Poppers" and Notice re Protease Inhibitors
-
Preventing Mother-Infant Transmission Worldwide: What Is Needed? Interview with Joseph Saba, M.D.
-
HIV Treatment Options
-
Community Organizing by Email: Needle Exchange Mobilization Example
-
15th Annual Candlelight March, May 17
-
San Francisco: Healing Alternatives Opens Castro Office
-
Issue #293, April 17, 1998
-
T-20 and Trimeris
-
Adefovir Dipivoxil (PREVEON) Improved Expanded-Access Program
-
Adefovir Dipivoxil (PREVEON) New Results with Hepatitis B, HIV
-
HIV/AIDS Nutrition Book for Clinicians
-
Treatment Conference Call May 2
-
Geneva Conference Communication Proposals for Minorities Due May 12
-
New Priority Email Delivery from AIDS Treatment News
-
Issue #292, April 3, 1998
-
AIDS Survival: Major Improvement Documented
-
Fatigue and HIV: Interview with Lisa Capaldini, M.D. Part II
-
Nevirapine: One-Year Combination Results Published
-
Notice on Efavirenz and Pregnancy
-
AIDSWatch May 3-5 in Washington
-
Medical Marijuana: Time to Contact Your U.S. Representative
-
California AIDS Lobby Day, April 20 in Sacramento
-
Issue #291, March 20, 1998
-
Future Directions
-
Fatigue and HIV: Interview with Lisa Capaldini, M.D.
-
1592 (Abacavir, or New Name Ziagen) More Widely Available March 23
-
CD4 Increase Despite Protease Inhibitor "Failure" in Swiss Study
-
March 25 Free Telephone Conference, "Choosing the Right HIV Treatment Strategy"
-
Women's HIV Treatment Workshop, Oakland, California, March 28
-
New FDA Commissioner Nomination Soon?
-
Issue #290, March 6, 1998
-
Drug Interactions: Resources for Patients and Professionals
-
Medical Marijuana Update:
- Medical Advances with International Impact:
Oral Contraceptive / Nevirapine Interaction Trial, New York and San Francisco
IL-2 Without Antiretroviral Therapy, Trial Near Washington D.C.
FDA Publishes Conflict of Interest Rules for Clinical Trials
Issue #289, February 20, 1998
-
Clinical Implications of Virological "Failure":
Interview with Steven Deeks, M.D., San Francisco General
Hospital
-
Retroviruses Conference Notes
-
Retroviruses Conference: For More Information
-
Opportunistic Infections: Major New Report
Issue #288, February 6, 1998
-
Organ Transplants: Interview with Jeff Getty, on Ending the
Exclusion of People with HIV
-
HIV/AIDS in Prison Project Threatened: Interview with Judy
Greenspan, Director
-
5th Retroviruses Conference in Chicago
-
Adefovir Dipivoxil (PREVEON): Expanded Access
Restrictions Being Eased
-
NTZ Submitted to FDA for Cryptosporidiosis
Issue #287, January 23, 1998
-
Marijuana, Inflammation, and CT-3 (DMH-11C): Cannabis Leads to New Class of Anti-inflammatory Drugs
-
Medical Marijuana: Federal, State Attacks Against California Cannabis Clubs
-
Medical Marijuana: The Will Foster Case in Oklahoma
-
Micronutrients and the HIV Patient, March 23-24 in Boston
-
Scholarships Available for Geneva Conference: Application Deadline March 8
-
More Attention to HIV Reporting As GMHC Changes Policy
Issue #286, January 9, 1998
-
1998 Outlook: Treatment, Research, Access
-
Efavirenz (Sustiva) Expanded Access Now to 400 CD4
-
San Francisco: Blood Needed for HIV Immunology Studies
-
Treatment Conferences and Meetings, 1998
1997
-
Issue #285, December 19, 1997
-
New Approaches to HIV Treatment: Interview with Robert Gallo, M.D.
-
1592 (Abacavir): Do Not Rechallenge After Hypersensitivity Reaction
-
Adefovir Dipivoxil (PREVEON) Expanded Access Begins
-
San Francisco: Eviction Legislation Protects Some with Major Illness
-
New York: One-Day Treatment Information Forum, January 17
-
AIDS Treatment News Index, 1997
-
Issue #284, December 5, 1997
-
Viral Immunology Advances Suggest Treatment Strategies
-
New Meeting on Immune Surrogate Markers, Baltimore, January 9-11
-
FDA Approves New Kind of Lymphoma Treatment
-
Major AIDS Institute Inaugurated in San Francisco
-
Protease Inhibitor Information: FDA Fact Sheet Available
-
Protease Inhibitor Failure Trial: Combination 1592, 141W94, and Efavirenz
-
New AIDS Bookstore on World Wide Web
-
Revised Federal Antiretroviral Treatment Guidelines
-
FDA Reform Signed into Law
-
Press Must Register Now to Cover February Retroviruses Meeting; December 29 Deadline
-
Correction: FORTOVASE Information Number for Patients in Washington D.C. Area
-
December Deadline for Charitable Giving and Tax Relief
-
Issue #283, November 21, 1997
-
FortovaseTM Approved: New Saquinavir Formulation
-
1592 Access: Larger Program Planned
-
HIV Resistance Testing: More Questions Than Answers
-
Drug-Resistant Herpes: Cidofovir Gel in Limbo. Interview with
Jay Lalezari, M.D.
-
Treatment in Developing Countries: New UNAIDS Pilot Program
-
Geneva Conference Deadlines: Time to Start Planning
-
Issue #282, November 7, 1997
-
HIV Research Overview: Interview with David Ho, M.D.
-
Expanded Access to Experimental Drugs: Activists Seek More Open Programs
-
AIDS Dementia: 1592 Now More Available
-
Qigong Exercise Program Airing in Los Angeles, Orange County; Tape Available
-
Correction: ICAAC Location
-
AIDS Service Organizations: Accountability Issue Surfaces in San Francisco
-
Issue #281, October 17, 1997
-
ICAAC Newspaper Headlines Misleading on Protease Inhibitor Failure
-
ICAAC: Online Summaries Available
-
Long-Term Strategies: Should Some Patients Wait to Start Protease Inhibitors? -- Interview with Keith Henry, M.D.
-
Delavirdine Combination and Viral Load
-
Linezolid, New Antibiotic Studied for MRSA, Available for Compassionate Use
-
International Conference on AIDS Wasting, Nov. 16-19, Fort Lauderdale, FL
-
Telephone Conference on Resistance and Cross-Resistance, Nov. 5, 1997
-
Telephone Conference on HIV Treatment Developments, Oct. 30
-
Money, Foundations, and the Public Agenda: Investigative Articles Available
-
Issue #280, October 3, 1997
-
Fifty Volunteer for Live-Vaccine Trial
-
37th ICAAC Conference, Toronto, Sept. 28 - Oct. 1
-
Unused Drugs Sought for Donation Abroad
-
Pregnant Women Eligible for Single-Dose Nevirapine
Study
-
ADAP, Research, and Prevention Funding, and Needle
Exchange,
Facing Decisions Now in Congress: Your Calls Important
-
"Poppers"--Annotated Reference List
Available
-
HMOs and Quality Care for HIV -- Interview with Stephen
Becker, M.D. (Part 2)
-
Issue #279, September 19, 1997
-
Engineered Virus Targets HIV-Infected Cells: Interview with Garry Nolan, Ph.D.
-
Efavirenz (SUSTIVATM) Expanded Access Begins October 1
-
Efavirenz (SUSTIVATM), Formerly DMP-266) 48-Week Data Announced
-
T-20: Entirely New Antiretroviral
-
IDSA '97: Conference Without Activists
-
IDSA '97: What It Did Right
-
IDSA '97: Excellent Medical Summaries on Tape
-
Issue #278, September 5, 1997
-
HMOs and Quality Care for HIV -- Interview with Stephen Becker, M.D.
-
Retroviruses Conferences Deadlines: Community Press and Scholarships November 3; Abstracts October 3; Late-Breaker January 5
-
DMP 266 Trials Recruiting, Many Cities -- Protease Inhibitor Naive
-
Adefovir Dipivoxil Trials: CD4 100-500, Protease Inhibitor Naive
-
Activism: Internet; San Francisco Workshop; Needle Exchange September 17; California Prison HIV Care
-
Virologic Failure; Managed Care; Treatment Rejectionists; Medical Research: GLMA Achievement Award Address
-
Issue #277, August 15, 1997
-
Protease Inhibitors' Metabolic Side Effects
-
Taxol Approved for Kaposi's Sarcoma
-
San Francisco: Changes at Conant Medical Group
-
IDSA Annual Meeting, September 12-16, San Francisco
-
1998 Retroviruses Conference: Deadlines Available Soon
-
AIDS Treatment News Must Increase Prices
-
Consensus Letter: Peter Duesberg
-
Issue #276, August 1, 1997
-
1592 Adult Compassionate-Use Program Announced
-
Returning to Work: Articles on Social
Security Rules
-
Federal AIDS Policy Issues Today
-
Issue #275, July 18, 1997
-
Health Insurance More Available:
Federal Legislation Effective July 1
-
Pediatric Trial of 141W94, Vertex
Protease Inhibitor
-
Pediatric 1592 Compassionate Use
Program Begins
-
World Wide Web AIDS Medical Information
-
Issue #274, July 4, 1997
-
New Standard of Care for HIV Disease
-
Major Pediatric Study Stopped Early:
Combination Treatment Better
-
Saquinavir: Major Study Shows Survival
Benefit in Treatment- Naive Patients
-
HIV Resistance International
Meeting: Summary on Web; Half- Day Meetings
-
National Summit Meeting on HIV Resistance, July 17 -- By Telephone
-
AmFAR Will End Support of CBCT Network,
Begin New Clinical Program
-
Internet Free Speech Upheld
-
AIDS CARE Newsletter
-
San Francisco, Healing
Alternatives: Help Wanted, Also Directors, Volunteers
-
California: AIDS Hotline Expands to
Cover State, Increases Hours
-
Issue #273, June 20, 1997
-
FDA Explores New Antiretroviral Trial
Designs: Interview with David Feigal, M.D.
-
Protease Inhibitors: FDA Warns Doctors of
Diabetes Risk
-
1592: Protests on Small Access Program
-
Help Wanted, Washington D.C.: "Network
Correspondent"
-
San Francisco, Oakland: Treatment
Access Workshop, June 27, July 11, July 18
-
Issue #272, June 6, 1997
-
Limited Immune Recovery After
Treatment with Antiretrovirals, IL-2
Interview with Clifford Lane,
M.D.
-
Viral Load in Clinical Trials: FDA
Advisory Committee Meeting July 14-15, 1997
-
Meetings Calendar, June 1997 - 1998
-
Issue #271, May 16, 1997
-
AIDS Treatment News Needs Your Support
-
Clinical Trials and Viral Load: Statement
for FDA Community Meeting May 16
-
1592: Small Distribution Programs Begin June, July
-
Indinavir (Crixivan(R)) Becoming
Available at Many Pharmacies
-
AIDS Internet: Treatment Information
Online
-
AIDS News on the World Wide Web: AEGIS (http://www.aegis.com) and Others
-
Help Wanted: Project Inform Seeks Hotline Manager
-
California: ADAP Program Adds Cidofovir, Nevirapine, and Nelfinavir
-
California: Seventh Annual AIDS Lobby Day, June 2
-
San Francisco: Lark Lands, Other Experts on Nutrition, Lean Body Mass, & Wasting, June 14
-
Issue #270, May 1, 1997
-
CMV, RS-79070: Community Concern As Major Drug's Development Suspended
-
CMV Retinitis, Newly Diagnosed: RS-79070 Trial
-
FDA Community Meeting May 16: Clinical Trials and Viral Load
-
HIV Vaccines Need to Be Developed: Interview with Sam Avrett, International AIDS Vaccine Initiative
-
1st National AIDS Malignancy Conference -- Online Summaries Available from April 28-30 Meeting
-
Medicaid: AIDS Impact of Proposed Cuts
-
Medical Marijuana: Questions Raised on San Francisco Raid
-
Issue #269, April 18, 1997
-
Delavirdine (Rescriptor(R)) Approved
-
Nelfinavir Combination Therapy:
Ten-Month Report
-
PMPA -- First Human Results
-
Standard Treatments for HIV, Mid 1997
-
ADAP Drug-Assistance Programs -- Funding Projections for 1998
-
Medicaid: Vice President Gore Supports Early Treatment
-
Medical Marijuana Wins Temporary
Restraining Order
-
AIDS/HIV TREATMENT DIRECTORY -- Mailing Address
-
Meetings Calendar for May 1997
-
Issue #268, April 4, 1997
-
New AmFAR Directory: Best Quick Reference for Mainstream Treatments
-
NAC, Glutamine, and Alpha Lipoic Acid
-
Costa Rican PWAs Seek Treatment Access - No Success in Roche Negotiations
-
Action Alert: Coburn Bill
-
AIDSWATCH '97: Advocacy in Washington, April 13-15
-
Issue #267, March 21, 1997
-
Ritonavir: New Approval for Children
-
HIV InSite: University of California AIDS Web Site
-
Acetylcarnitine: Call for Information
-
SPV-30: FDA Stops Distribution Over
Advertising
-
It's Time to Approve More Surrogate Markers
-
AIDS Treatment Activism: Focus on Service
-
Issue #266, March 7, 1997
-
Stanford NAC Study: Glutathione Level Predicts Survival
-
Glutathione-Depleting Drugs: Petition to the FDA
-
AIDS Survival: First Drop in Total Deaths in U.S.; Larger Drop in France
-
Protease Inhibitors: Major Study Stopped When 3-Drug Arm Proves Superior
-
Help Wanted: GMHC Treatment Education Director
-
San Francisco: Cattle Grazing, Reservoirs, and Cryptosporidiosis
-
Issue #265, February 21, 1997
-
Fewer AIDS Deaths and Illnesses: New
Information
-
Nelfinavir -- Major Trial Results at
Retroviruses Conference
-
DANGER: Possibly Fatal Interactions Between Ritonavir and "Ecstasy," Some Other Psychoactive Drugs
-
Free Viral Load Tests Becoming Available for Uninsured Patients
-
ABT-378: Abbott "Second Generation" Protease Inhibitor
-
Drug-Related Neuropathy: Low Acetylcarnitine Levels Found
-
San Francisco: 9th National AIDS Update Conference, March 18-22
-
New York: Management of the HIV-Infected
Patient, March 7-9
-
New York: ACT UP 10-Year Anniversary: Activist Conference March 22-23, Wall Street Demo March 24
-
Retroviruses Conference Information: Tape Sales; Email Access
-
Medical Marijuana: New Nationwide Poll Shows 2-1 Public Support
-
Medical Marijuana: Followup on THC
Toxicology Report
-
Issue #264, February 7, 1997
-
Retroviruses Conference Overview:
Consolidating the Advances
-
Retroviruses Conference: Where to Get Information
-
Low Vitamin B-12 Blood Levels Associated with Faster Progression to AIDS
-
Adefovir Dipivoxil: Broad-Spectrum
Antiviral Trial, CD4 Count Under 100
-
Opportunistic Infections: Major Report
Available
-
Acyclovir-Resistant Herpes: Expanded Access Available for Cidofovir Gel
-
Protease Inhibitor Failures: Call for
Information
-
Non-Approved Liver Treatments: Call for
Information
-
Retroviruses Conference Excludes People with AIDS, Researchers, and Physicians
-
Issue #263, January 17, 1997
-
1997 Outlook
-
Nelfinavir: Agouron Announces Expanded Access for Children, a Major New Trial, and Enlarged Expanded Access for Adults
-
Retroviruses Conference: Where to Find
Reporting on the Internet
-
Medical Marijuana: Unpublished Federal Study Found THC-Treated Rats Lived Longer, Had Less Cancer
-
Activist Groups and PWA Coalitions, U.S. and Canada
-
Issue #262, January 3, 1997
-
Hundreds Turned Away from National Retroviruses Conference in January
-
Retroviruses Conference: Daily CME Reports Available on World Wide Web
-
AIDS Conference Information on the Internet -- How to Present It
-
San Francisco: Vocational Counseling
Workshops
1996
-
Issue #261, December 20, 1996
-
Viral Load Seminars in January and February, Eight U.S. Cities
-
d4T+AZT -- Unexpected CD4 Drop Seen in Study
-
1592: Consensus Letter on Access to New Glaxo Drug
-
Call for Research on Better Use of Existing Drugs in Advanced Disease
-
National Conference on Women and HIV -- Late Breaker Deadline March 21
-
Geneva AIDS Conference Seeks Community Planning Coordinator
-
Vaccine Report Available
-
Reminder: AIDS Treatment News Reader Survey
-
Medical Marijuana: Legal Issues for
Physicians and Others
-
Marijuana and Research
-
AIDS Treatment News 28-Page Index
-
AIDS Treatment News Index for 1996
-
Issue #260, December 6, 1996
-
Buyers' Club Crisis -- Challenge for AIDS
Communities
-
Fewer AIDS Deaths: San Francisco Information
-
FDA Advisory Committee Deadlocks on Delavirdine
-
Albendazole Free from Buyers' Club
-
Books: Impure Science
-
Buyers' Clubs List, December 1996
-
AIDS Treatment News Reader Survey
-
Issue #259, November 15, 1996
-
Birmingham UK Drug Therapy Conference -- Early Report
-
Federal Team Developing Treatment Principles for HIV Infection
-
1592: Two Studies Recruiting
-
The New Antiretroviral Arsenal
-
Medical Marijuana Wins in California and
Arizona
-
FDA Internet Regulation? Public Comment
Accepted until December 16
-
AZT Twice-Daily Tablets Approved; Dosing
Concerns
-
Retroviruses Conference: Press Deadline
December 6
-
Qigong Program on San Francisco KQED TV, Beginning December 7
-
Issue #258, November 1, 1996
-
HCG: New Kind of KS Treatment?
-
IL-2: Controlled Trial Finds Major CD4
Increases
-
NTZ for Cryptosporidiosis: Larger Expanded
Access; Buyers' Club/FDA Conflict
-
International Treatment Access and Research,
How You Can Help -- Interview with Dr. Peter Piot of UNAIDS
-
Retroviruses Conference -- Some Scholarships Available
-
Starting and Changing HIV Treatment:
Conference Call Nov. 5, Recording Later
-
TREATMENT ISSUES Article on New Therapies After Protease Inhibitors
-
AIDSACT, New Email List for Activists
-
Hepatitis C: Protease Structure of Virus
Published
-
Bioethics: Major Meetings in San Francisco,
November 20-25
-
Issue #257, October 18, 1996
-
Medical Marijuana: The State of the Research
-
Marijuana and Chocolate
-
Large Combination Trials with AZT, ddI, ddC: Results Published
-
Viral Load Access Consensus Statement
-
Viral Load Seminars for Physicians --
Rescheduled
-
PhRMA Drops Lawsuit on Government Drug Pricing
-
Benefits Planning: What You Must Know (Part II)
-
Issue #256, October 4, 1996
-
Grassroots Organizing by Internet: An Example
-
CKR-5: New Study Confirms Some Do Not Get HIV
-
Ritonavir and Saquinavir Combination: 12-Week Data at ICAAC
-
Pharmaceutical Industry Sues to Stop Discount Pricing to Clinics
-
Congress, Late September 1996: Funding, ADAP, Immigration
-
3TC Clinical Benefit: More Data Presented
-
CMV Information: Print, Online, Phone, Video
-
Viral Load Seminars for
Physicians: Late October Dates in U.S. Cities
-
Viral Load Overview Available from Treatment Action Group
-
Washington, October 7: Promoting Treatment and Care in Developing Countries
- Benefits: San Francisco Training, November 1
-
Issue #255, September 19, 1996
-
Retroviruses Conference Sets January 22-26 1997 Meeting Dates: Abstract Deadline October 16
-
Nelfinavir (Viracept) Expanded Access Announced
-
ICAAC Conference AIDS Overview -- Available by Toll-Free Phone Call
-
Washington AIDS Events: Major Demonstrations October 11, 12, and 13
-
Benefits Planning -- What You Must Know:
Interview with Daniel Fortuño, AIDS Benefits Counselors (Part I)
-
Issue #254, September 6, 1996
-
Human Growth Hormone Approved for Wasting
-
ddI plus d4T
-
Ritonavir Plus Saquinavir: Two Trials
With Different Results
-
CKR-5 -- Understanding the News
-
HIV Sensitivity Testing: Organizing for Access
-
Register to Vote: Time Running Out
-
AIDS Treatment News Associates (ATNA) Receives Nonprofit Status
-
Issue #253, August 23, 1996
-
Nelfinavir Protease Inhibitor Study Recruiting
-
Five-Drug or Six-Drug Antiretroviral Therapy
-- Conversation with Steven Scheibel, M.D.
-
1592 -- New Experimental Antiretroviral
-
Medical Marijuana: California Update
-
Calendar of AIDS Research and Treatment
Meetings, Late 1996
and Beyond
-
Issue #252, August 2, 1996
-
Editorial: Time to End the Death Trials
-
3TC: Combination Trial Stopped Early As Clinical
Benefit Shown
-
ADAP Treatment-Access Emergency -- Interview
with William
Arnold, ADAP Working Group
-
Reminder: Free Viral Load Testing From
Roche, Only Until
August 16
-
San Francisco Area: "Highlights from
Vancouver" at Kaiser
Oakland, August 20
-
DHEA: Modest Viral Load Reduction in Patients
-
San Francisco Cannabis Buyers' Club Raided Aug. 4
-
Issue #251, July 19, 1996
-
Vancouver in Perspective
-
New View of Antiretroviral Treatment:
Illustrations from "Late Breaker" Abstracts
-
Expert Panel's New Recommendations for
Antiviral Treatment
-
After Vancouver: Documenting Improved
Survival
-
Issue #250, July 5, 1996
-
Cryptosporidiosis: NTZ at
Buyers' Club; Customs Holds Second Shipment
-
NAC: First Controlled Trial, Positive Results
-
Nevirapine Approved
-
Vancouver Conference: Each Day Summarized
Nightly on World Wide Web
-
SCIENCE Publishes Major AIDS Issue June 28;
Full Text on Web
-
CMV Retinitis and Treatment: CME Course on
World Wide Web
-
Delavirdine Expanded Access Program
Information on World Wide Web
-
West Hollywood: AIDS and Chinese Medicine
Conference, July 25-28
-
Neuropathy: Nutrient Therapies
-
World Wide Web: AIDS Treatment News Lists
Over 100 Sites
-
Issue #249, June 21, 1996
-
New Optimism on Controlling HIV Infection
-
Internet Free Speech Wins Court Test
-
Azithromycin Approved for Once-Weekly
MAC Prophylaxis
-
Nevirapine Recommended for Approval
-
Free Viral Load Tests: Remember to Dial 1
Before 888
-
Needlestick Exposure: CDC Recommends
Three-Drug Regimen
-
AIDS and Alternative Medicine: A Journalist's
Perspective
-
Issue #248, June 7, 1996
-
Viral Load Approved; Free Test Offered to All
in U.S. with HIV
-
Viral Load: New Recommendations for Clinical
Practice
-
Viral Load: New Proof of Importance for
Disease Staging and Prognosis
-
Op Ed: Viral Load FDA Approval Delays
-
PMPA: New Information
-
3TC: Glaxo Wellcome Broadens Patient
Assistance
-
Prison: California Conference on HIV and
Prison Issues, Oakland, June 27
-
AIDS Treatment News New Index Available
-
Activist Communications, Activities at
Vancouver Conference
-
"Access for All": Communication Strategy
Proposal for International Conference
-
Issue #247, May 17, 1996
-
NIH Scientists Find Cofactor for HIV Entry
-
World Medicine and Western Medicine: The
Missing Dialog -- Interview with Kaiya Montaocean, Co-Director, Center for
Natural and Traditional Medicines
-
Workshop on Traditional Healing and
Policy, June 13 Near Washington, D.C.
-
AIDS Treatment News Back Issues on Web
-
Best Internet, Computer Sites on AIDS: Request
for Information
-
Computer Communication in Developing
Countries: Request for Information
-
AIDS and Media in Developing Countries:
Request for Information
-
Pharmaceutical Contributions and
AIDS Organizations: Request for Input
-
AIDS Treatment News Policy on
Pharmaceutical-Company Revenue
-
Issue #246, May 3, 1996
-
Saquinavir: Combination Shows Survival
Benefit; New Formulation Trial Recruiting
-
Improved HIV Survival Indicates Effect of
Therapy
-
Kaposi's Sarcoma: DaunoXome(R) Approved
-
Crixivan(R) Price: Behind the Reduction
-
California: 3TC Now Available through
ADAP
-
Women and HIV: Conference Calls May 14 and
May 15, on Treatment Concerns
-
Alternative Treatments for HIV:
Nationwide Survey Seeks Users
-
Federal Policy: Ryan White, OAR, Testing
Newborns
-
AIDSWatch 1996: National Lobbying Days in
Washington, May 19-21
-
Paris Conference on NAC, Similar Therapeutic
Approaches, May 21-23
-
Vancouver Conference Satellite Meetings,
Part II
-
Issue #245, April 19, 1996
-
Crixivan(R) Price Break for Cash
Customers: $97 Per Month Less, If You Ask
-
Protease Inhibitors: Ritonavir and
Saquinavir Combination Trial Recruiting
-
Protease Inhibitors: Background
Information
-
Delavirdine Available on Expanded
Access
-
Sinusitis: Helpful Background, Treatment
Article
-
Chinese Medicine: Qigong Exercise Tape
Available
-
rGP-160 Treatment Vaccine (VaxSyn):
Canadian Study Finds No Benefit
-
FDA Reform in Congress: Interview with Peter
Barton Hutt
-
FDA Reform in Congress: FDA's Concerns
-
Vancouver Conference: Make Travel Plans
Now. Focus, Program, & Satellite Meetings
-
Issue #244, April 5, 1996
-
San Francisco: 3TC Available Now to Residents
through ADAP Program
-
Protease Inhibitors: Patient Education
Critical
-
Indinavir (Crixivan(R)) Access and
Distribution
-
AIDS Research at NIH: Study Panel Issues Major
Report
-
Viral Load: Inconclusive FDA Hearing
-
AZT, ddI, and ddC Combinations at FDA Advisory
Hearing
-
Cidofovir Recommended for Approval for
CMV Retinitis
-
California: Clinical Trials Computer
Service Now Available Statewide
-
San Francisco Protest Against Meeting
Disruptions
-
California: AB 2812 Would Outlaw Anonymous
Testing
-
AIDS Medications Needed Abroad
-
Issue #243, March 15, 1996
-
Indinavir (Crixivan(R)), Merck Protease
Inhibitor, Approved
-
Ritonavir (NORVIR(TM)), Abbott Protease
Inhibitor, Approved
-
Protease Inhibitors at FDA Advisory
Hearings
-
FDA Antiviral Hearings: Community Perspectives
-
FDA Hearings: For More Information
-
Human Growth Hormone Not Recommended for
Approval on Narrow Advisory Panel Vote
-
Consensus Statement on the Further
Development of Protease Inhibitors And Human Growth Hormone
-
AIDS and Alternative Medicine, Seattle, April
28
-
Issue #242, March 1, 1996
-
Curcumin: Clinical Trial Finds No
Antiviral Effect
-
Protease Inhibitor Approvals -- Will
People Be Cut Off Drug? Followup Studies Proposal Needs Support
-
Rolipram: Antidepressant Used in Europe
and Japan Might Have Promise Against TNF, HIV
-
Study Finds AIDS Patients Live Longer When
Their Doctors Have More Experience Treating HIV
-
Protease Inhibitors at Retroviruses
Conference: Agouron's Results
-
Retroviruses Conference: Obtaining
Copies of Abstracts
-
DHEA: Threat to Access?
-
Issue #241, February, 1996
-
Merck Protease Inhibitor: More News from
Retroviruses Conference
-
d4T Plus ddI Antiviral Results
-
Growing Crisis in Paying for Care
-
AB 9: California Bill Would End County Mandate
for Last- Resort Care, Including Communicable Diseases
-
Press Gag Rules at AIDS Conference
-
Issue #240, February 9, 1996
-
Protease Inhibitors at Retroviruses
Conference
-
Protease Inhibitors in Human Testing:
Annotated List
-
Ritonavir (Abbott Protease Inhibitor)
Proves Survival Benefit in Late-Stage AIDS
-
Agouron Starts Phase III Protease Inhibitor
Studies
-
Vancouver International Conference:
Community Booths Deadline Extended
-
FDA Antiviral Advisory Committee Meetings This
Month
-
Prisoners: Send Address Updates;
Contacting Organizations
-
NMAC Skills Building Conference in South
Africa: Facilitators Wanted
-
Computer Censorship Law, ACLU Test Case,
Begin February 8
-
Issue #239, January 19, 1996
-
NTZ: Cryptosporidiosis New Treatment
-
Viral Load: New Confirmation from Major
Delavirdine Studies
-
Protease Inhibitor Update: Treatment
Combination Strategies
-
Ritonavir: Expanded Access Begins,
Warning on Drug Interactions
-
Stanford NAC Study, San Francisco, Needs
to Contact Screened Applicants and Participants for Followup
-
Needle Exchange: Experts Deplore Shalala
Remarks
-
Retroviruses Conference Notes
-
DHEA and AIDS
-
DHEA Clinical Experience: Interview with Jon
Kaiser, M.D.
-
Issue #238, January 5, 1996
-
Getting Your Insurer to Cover New HIV
Treatments: A Crash Course
-
CD8 Cells: Suppressive Factors Discovered
-
AZT plus 3TC Combination Results Published
-
Opportunistic Infection Prevention: National
Video Symposium January 11
-
San Francisco: Cryptosporidiosis Water
Warning
-
Computer Censorship Update
-
Activist Groups, PWA Coalitions, and Buyers'
Clubs, U.S. and Canada
1995
-
Issue #237, December 22, 1995
-
Saquinavir (Invirase): First Protease
Inhibitor Approved -- Reimbursement, Info Numbers
-
Abbott Protease Inhibitor Lottery in
January, CD4 Under 50 -- Registration Now
-
Abbott Protease Inhibitor: Early Results
Reported
-
Major Protease Inhibitor Triple
Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive
-
Wasting Syndrome: Oral Oxandrolone
Re-Released in U.S.
-
Lymphoma: MGBG New Studies, Compassionate
Use in Earlier Disease
-
Human Retroviruses, Immune-Based, and CPCRA
Meetings, Wash. D.C. Late Jan.
-
ACTG Clinical Trial Sites: Seven Cut,Two Added
-
New York: Protease Inhibitor Forum, January
6
-
Computer Censorship: Effect on AIDS
TREATMENT NEWS
-
Issue #236, December 1, 1995
-
Lamivudine (3TC) Approved for
Combination Use with AZT
-
PMPA in Perspective
-
DOXIL Approved for KS
-
New Double Vs. Triple Antiviral Combination
Study, CD4 200-500, No Prior Treatment
-
Internet Censorship: Congress Moves Toward
Final Decision
-
Issue #235, November 17, 1995
-
Protease Inhibitors: Drug Resistance and
Cross Resistance Overview
-
Grapefruit Juice and Saquinavir
-
FDA Reform: New Senate Bill
-
Issue #234, November 3, 1995
-
Thalidomide for Wasting Syndrome:
Progress Toward Compromise
-
CMV: Oral Ganciclovir for Prevention
-
CMV: New Screening Program
-
Cryptosporidiosis Information Phone/Fax Line
-
Peptide T: Negative Trial Result
-
Issue #233, October 20, 1995
-
Viral Load: New "Strategy" Trial in
15 U.S. Cities
-
International Conference, Vancouver
1996: Arrangements and Deadlines
-
San Francisco Area: Testosterone
Replacement Study, Injection vs. Patch
-
Issue #232, October 6, 1995
-
Protease Inhibitors and Prevention of
Cross Resistance
-
AZT Delta Study: Major European/Australian
Study Finds Combinations Better Than AZT Alone
-
Los Angeles, New York, Stanford University:
HBY 097, New Drug May Weaken HIV
-
ICAAC's Small Advances
-
AIDS Information Obstacles
-
Issue #231, September 29, 1995
-
ICAAC 1995: New Perspectives on Treatment
-
Major Study Shows AZT Monotherapy Inferior
-
Abbott Protease Inhibitor In Combination:
Sustained Viral Load Drop
-
Agouron Protease Inhibitor
-
Saquinavir (Roche Protease Inhibitor) At
Higher Doses
-
Ritonavir, Saquinavir Combination -- and
Warning
-
Symptom-Reduction Trials at FDA Clinical
Trials Workshop
-
Medicaid in Congress: Serious Threat to
Health Care
-
Issue #230, September 1, 1995
-
Acupuncture and Chinese Medicine;
Interview with Tom Sinclair, L. Ac.
-
Hydroxyurea and ddI: French Study
Published
-
Thalidomide: New Expanded Access for
Wasting
-
Health Insurance: Widespread Copayment
Abuse
-
Issue #229, August 18, 1995
-
"Confirmatory" Trials: Symptom
Reduction As Efficacy Measure
-
FDA Warning on Raw Oysters
-
Is NIH AIDS Research in Danger?
-
Issue #228, August 4, 1995
-
New Antiretroviral Strategies: Interview
with Marcus Conant, M.D.
-
3TC: Now Available Again Up To CD4 of 300
-
California: Medi-Cal Can Pay for Human
Growth Hormone for Some Patients
-
FDA Reform: Activists' Proposals
|
|
Advertisement
|